VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market
完整報告名稱與涵蓋範圍
VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market, Share & Trends Analysis Report, By Drug Type (Aflibercept, Ranibizumab, Bevacizumab, Faricimab, Biosimilars, Pipeline drugs), By Indication (Diabetic Macular Edema (DME), Proliferative. Diabetic Retinopathy (PDR), Non-Proliferative Diabetic Retinopathy (NPDR)), By Delivery Method, By Region, and Segment Forecasts, 2025-2034
報告摘要
The global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market is expected to accelerate at a compound annual growth rate of 6.8% throughout the 2025–2034 forecast period.
VEGF Inhibitors Therapeutic for Diabetic Retinopathy covers a standard treatment for diabetic retinopathy, particularly in cases of proliferative diabetic retinopathy (pdr) and diabetic macular edema . Rapid advancements and evolving end-user preferences are reshaping how healthcare entities approach this space.
Several factors contribute to this trajectory, including heightened requirement next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
From a regional perspective, mature markets in North America and Europe continue to hold meaningful shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and surging investment in the sector.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Snapshot
Chapter 4. Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on VEGF Inhibitors Therapeutic for Diabetic Retinopathy Industry Trends
4.10. Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Segmentation 1: By Drug Type, Estimates & Trend Analysis
5.1. Market Share by Drug Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:
5.2.1. Aflibercept (Eylea)
5.2.2. Ranibizumab (Lucentis)
5.2.3. Bevacizumab (Avastin, off-label)
5.2.4. Faricimab (Vabysmo, dual VEGF/Ang-2 inhibitor)
5.2.5. Biosimilars
5.2.6. Pipeline drugs
Chapter 6. VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Segmentation 2: By Indication, Estimates & Trend Analysis
6.1. Market Share by Indication, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
6.2.1. Diabetic Macular Edema (DME)
6.2.2. Proliferative Diabetic Retinopathy (PDR)
6.2.3. Non-Proliferative Diabetic Retinopathy (NPDR)
Chapter 7. VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Segmentation 3: By Delivery Method, Estimates & Trend Analysis
7.1. Market Share by Delivery Method, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Method:
7.2.1. Intravitreal Injections
7.2.2. Sustained-Release Implants
7.2.3. Emerging
Chapter 8. VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.2.3. North America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.2.4. North America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
8.3. Europe
8.3.1. Europe VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.3.3. Europe VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.3.4. Europe VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.4.3. Asia Pacific VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.4.4. Asia Pacific VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
8.5. Latin America
8.5.1. Latin America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.5.3. Latin America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.5.4. Latin America VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
8.6.3. Middle East & Africa VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
8.6.4. Middle East & Africa VEGF Inhibitors Therapeutic for Diabetic Retinopathy Market Revenue (US$ Million) Estimates and Forecasts by Delivery Method, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Regeneron Pharmaceuticals, Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Drug Type/Service Overview
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Blue Diamond Growers, Inc.
9.2.3. F. Hoffmann-La Roche Ltd.
9.2.4. Novartis AG
9.2.5. Bayer AG
9.2.6. Genentech, Inc. (Roche subsidiary)
9.2.7. Kodiak Sciences Inc.
9.2.8. Innovent Biologics, Inc.
9.2.9. Ashvattha Therapeutics, Inc.
9.2.10. UNITY Biotechnology, Inc.
9.2.11. PanOptica, Inc.
9.2.12. Regenxbio Inc.
9.2.13. Ocular Therapeutix, Inc.
9.2.14. Adverum Biotechnologies, Inc
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們